Kolexia
Biotti Damien Neurologie
Biotti Damien
Neurologie
Hôpital Purpan
Toulouse, France
161 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sclérose en plaques Sclérose Neuromyélite optique Névrite optique Névrite Sclérose en plaques récurrente-rémittente Leucoencéphalopathies Accident vasculaire cérébral Leucoencéphalopathie multifocale progressive

Collaborateurs

Voir plus
Ciron Jonathan
Ciron Jonathan
Hôpital Purpan, Toulouse, France
Brassat David
Brassat David
Hôpital Pitie Salpetriere, Paris, France
De Sèze Jérôme
De Sèze Jérôme
Hôpital Hautepierre, Strasbourg, France
Labauge Pierre
Labauge Pierre
Hôpital Gui de Chauliac, Montpellier, France

Industries

Voir plus
Novartis
47 collaboration(s)
Dernière en 2023
Merck-Serono
10 collaboration(s)
Dernière en 2022
Biogen
9 collaboration(s)
Dernière en 2023
Wedo studios
6 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
Multiple sclerosis (Houndmills, Basingstoke, England)   21 janvier 2024
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England)   02 janvier 2024
Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease.
Journal of neurology, neurosurgery, and psychiatry   27 octobre 2023
Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases.
International immunopharmacology   03 juin 2023
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.
JAMA network open   01 juin 2023
NeurofilMS: Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Essai Clinique (CHU Nîmes)   03 mai 2023
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
Frontiers in immunology   23 mars 2023
Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort.
Neurology and therapy   10 février 2023
2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us.
Multiple sclerosis and related disorders   10 février 2023
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study.
Neurology(R) neuroimmunology & neuroinflammation   14 novembre 2022